Curriculum Vitae

Cellular, Tissue and Gene Therapies Advisory Committee

Walter John Urba, MD, PhD

NAME: Walter John Urba, M.D., Ph.D., F.A.C.P.
DATE OF BIRTH: -------------------------
PLACE OF BIRTH: -------------------------
CITIZENSHIP: -------------------------
SSN: -------------------------
MARITAL STATUS: -------------------------
PRESENT ADDRESS:
Home: -------------------------
-------------------------
Work: Robert W. Franz Cancer Research Center
Earle A. Chiles Research Institute
Providence Portland Medical Center
4805 N.E. Glisan St., 5F-40
Portland, OR 97213
TELEPHONE:
Home: -------------------------
Work: -------------------------      e-mail: walter.urba@providence.org

EDUCATION:
----------- B.A., Rutgers University, New Brunswick, New Jersey, Biological Sciences
1977 Student, Short Course in Mammalian Genetics, The Jackson Laboratory, Bar Harbor, Maine
----------- Ph.D., Department of Microbiology and Immunology, School of Medicine, University of California at Los Angeles, California Professor William H. Hildemann, major preceptor
1979 Postdoctoral Fellow, Laboratory of Professor William H. Hildemann
----------- M.D., University of Miami, Miami, Florida (Ph.D. to M.D. Program)
1981 - 1983 Medical Resident, Morristown Memorial Hospital, Morristown, New Jersey, Affiliate - Columbia University College of Physicians and Surgeons
1983 - 1986 Clinical Staff Fellow, Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
 
CHRONOLOGY OF EMPLOYMENT:
1975 - 1976 Medical Sales Representative, Marion Laboratories, Kansas City, Missouri
1986 - 1989 Head, Clinical Immunology Services, Program Resources, Inc., National Cancer Institute Frederick Cancer Research and Development Center, Frederick, Maryland
1990 - 1993 Director, Clinical Services Program, Program Resources, Inc./DynCorp, National Cancer Institute - Frederick Cancer Research and Development Center, Frederick, Maryland
1993 - 1994 Medical Oncologist, Hematology Clinic Portland, Oregon
1994 - 2000 Medical Oncology; Oregon Hematology Oncology Associates, Portland, Oregon
2001- Date Medical Oncologist; The Oregon Clinic - The Medical Oncology Division, Portland, Oregon
1993 - Date Medical Director, Cancer Program and Director, Cancer Research, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon
 
ACADEMIC APPOINTMENTS:
1994 - Date Clinical Associate Professor in the Department of Medicine, Division of Hematology and Medical Oncology, School of Medicine, Oregon Health Sciences University, Portland, OR
1996 -1998 Interim Associate Director for Clinical Research, Oregon Cancer Center, Oregon Health Sciences University, Portland, Oregon
1998 - Date Affiliate Investigator, Division of Clinical Research, Fred Hutchison Cancer Research Center, Seattle, Washington
 
ACADEMIC HONORS:
1973 - 1974 Henry Rutgers Honors Research Program, Rutgers University
1976 - 1977 California Regents Scholar
1977 - 1979 USPHS National Research Service Award Trainee
1993 National Institutes of Health Award of Merit "for the development of the first cytokine therapy capable of significantly accelerating platelet recovery after high-dose chemotherapy."
 
MEDICAL SPECIALTY BOARDS:
  Diplomate, American Board of Internal Medicine, 1985 -#--------
Diplomate, American Board of Medical Oncology, 1987 -#--------
 
 
PROFESSIONAL LICENSE:
  License # --------- - Maryland (Inactive)
License # -------- - Oregon
 
PROFESSIONAL MEMBERSHIPS:
  Member, American Association for Cancer Research
Member, American Association of Immunologists
Fellow, American College of Physicians
Member, American Society Clinical Oncology
Member, Clinical Immunology Society
Member, Federation of American Societies for Experimental Biology
Member, Oregon Medical Association
Member, Puget Sound Oncology Consortium
Member, Society for Biological Therapy
 
COMMITTEES AND ADMINISTRATIVE SERVICE:
1990 Session Co-Chair, Immunology and Cancer Biology, ASCO
1992 Member, Program Committee, ASCO
1992 Session Co-Chair, Tumor Immunology, ASCO
1993 - 1998 Member, Executive Committee, Oregon Cancer Center
1993 - Date Member, Melanoma, Immunomolecular & Genitourinary Committees, Southwest Oncology Group (SWOG)
1998 - 2000 Member, Program Committee, ASCO
1998 - Date P01 Site Visits, NCI/NIH (ad hoc reviewer)
1999 - 2002 Clinical Oncology Study Section, NCI/NIH
2000 - 2001 Member, Program Committee, ASCO
2003 - 2004 Clinical Oncology Study Section, NCI/NIH (Permanent Member)
2004 Chair, Educational Session for Melanoma, ASCO
2004 Co-Chair International Society for Biological Therapy of Cancer, Immunological Immunotherapy Workshop
2004 - Date Scientific Advisory Board, PacMab
2005 - Date FDA Cellular, Tissue and Gene Therapies Advisory Committee
 
EDITORIAL BOARDS:
1986 - 1997 Co-Editor, Clinical Oncology Alert
1997 - Date Journal of Immunotherapy
1998 - 1999 Assoc. Editor, Year Book of Oncology. St. Louis, Mosby-Year Book, Inc. Publisher
 
AD HOC REVIEWER:
1989-Present Journal of Clinical Oncology
Journal of the National Cancer Institute
Cancer Research
CA--A Cancer Journal of Clinicians
Annals of Internal Medicine
Radiation Research
USP Drug Information Division
Journal of Immunology
International Journal of Immunopharmacology
Journal of Laboratory and Clinical Medicine
Blood
Cancer
Mayo Clinic Proceedings
Clinical Breast Cancer
Clinical Cancer Research
Journal of Imunotherapy
 
PEER REVIEW GRANT FUNDING: ONGOING OR COMPLETED IN LAST THREE YEARS

Principal Investigator: Immune response to the mutated gp100 peptide (209-2M). National Institutes of Health/National Cancer Institute #1-R21-CA-82614-01. [July 1, 1999 - June 30, 2001. 10% effort/$0 closed.]

Co-Investigator: Immunological Correlates of Effective Immunization of Cancer Vaccines. National Institutes of Health/National Cancer Institute # 1-U54-CA90818-01, University of Washington; Mary L. Disis, MD Investigator. [July 1, 2001 - December 31, 2006. 2.1% effort.]

Co-Investigator: Development of Effective Immunotherapy for Prostate Cancer Patients. Department of Defense # DAMD 17-03-1-0097. [April 1, 2003-March 31, 2006 5% effort/$0.]

Principal Investigator: Peptide Booster Vaccination in A2+ Melanoma Patients. National Institutes of Health/National Cancer Institute #1-R21 CA 099265-01 A2. [April 1, 2004-March 31, 2006 10% effort$0.]

Principal Investigator: gp100 Peptide immunization after lymphocyte depletion. National Institutes of Health/National Cancer Institute R21 CA 101325-02. [September 10, 2003-August 31, 2005 10% effort/$0.]

Co-Investigator: Clinical development of anti-OX40 and OX40L. National Institutes of Health/National Cancer Institute #1-R01 CA109563-01. [July 1, 2004-June 30, 2009 5% effort/$0.]

  1. Urba, W.J., Hildemann, W.H.: H-2 linked recessive Ir gene regulation of high antibody responsiveness to TNP hapten conjugated to autologous albumin. Immunogenetics 6:433-445, 1978.

  2. Urba, W.J., Hildemann, W.H.: Functional analysis of H-2-linked genetic control of immune responsiveness to TNP-MSA. J. Immunol. 123:209-215, 1979.

  3. Wicker, L.S., Urba, W.J., Hildemann, W.H.: Hierarchy of H-2 haplotypes governs inheritance of immune responsiveness to TNP-MSA. Immunogenetics 10: 235-246, 1980.

  4. Rhodes, J.C., Wicker, L.S., Urba, W.J.: Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29: 494-499, 1980.

  5. Wicker, L.S., Kenny, J.J., Urba, W.J., Hildemann, W.H.: H-2 hierarchy in the Ir - gene controlled responses to hapten-modified mouse serum albumin. Dev. and Comp. Immunol. 8(2):425-434, 1984.

  6. Urba, W.J., Longo, D.L.: Cytologic, immunologic and clinical diversity in non-Hodgkin's lymphoma: Therapeutic implications. Sem. Oncol. 12:250-267, 1985.

  7. Urba, W.J., Longo, D.L.: Clinical spectrum of human retroviral induced diseases. Cancer Res. 45:4637s-4643s, 1985.

  8. Seifter, E.J., Brooks, B.J. Jr., Urba, W.J.: Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep., 69(2): 244-5, 1985.

  9. Urba, W.J., Longo, D.L.: Primary solid tumors of the heart. In Kapoor, A.S. (Ed.): Cancer and the Heart. New York, Springer-Verlag, 1986, 62-75.

  10. Urba, W.J., Longo, D.L.: Alpha interferon in the treatment of nodular lymphomas. Semin. Oncol. 13:40-47, 1986.

  11. Klainer, A.S., Urba, W.J., Katz-Pollak, H.: Anaerobic osteomyelitis: A serious sequela of diabetes. Infections in Medicine, 1986.

  12. Urba, W.J., Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/9. Amsterdam, Elsevier Science Publishers B.V., 1987, 473-483.

  13. Urba, W.J., Longo, D.L.: T cell lymphoma. In Carbone, P.P. (Ed.): Current Therapy in Hematology/Oncology. B.C. Decker, Inc. Toronto, 1987, 297-302.

  14. Lipford, E., Wright, J.J., Urba, W.J., Whang-Peng, J., Kirsch, I.R., Raffeld, M., Cossman, J., Longo, D.L., Bakhshi, A., Korsmeyer, S.J.: Refinement of lymphoma cytogenetics by the 18q21 major break point region. Blood 70: 1816-1823, 1987.

  15. Urba, W.J., Maluish, A.E., Longo, D.L.: Strategies for immunological monitoring. In Pinedo, H.M., Longo, D.L., Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/9. Amsterdam, Elsevier Science Publishers B.V., 1987, 484-501.

  16. Stevenson, G.W., Hall, S., Rudnick, S.J., Alvord, G., Rossio, J., Urba, W.J., Leventhal, J.B., Miller, P., Seleny, F., Stevenson, H.C.: Halothane anesthesia decreases human monocyte hydrogen peroxide generation. Protection of monocytes by activation with gamma interferon. Immunopharmacol. Immunotoxicol. 9(4): 489-510, 1987.

  17. Elliott, K.R.F., Princler, G.L., Urba, W.J., Faltynek, C.R.: Synergistic antiproliferative effects of glucocorticoids and interferon-alpha on some lymphoid cell lines. J. Cell Physiol. 134:85-92, 1988.

  18. Maluish, A.E., Urba, W.J., Longo, D.L., Overton, W.R., Coggin, D., Crisp, E.R., Williams, R., Sherwin, S.A., Gordon, K., Steis, R.G.: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J. Clin. Oncol. 6:434-445, 1988.

  19. Lawrence, T.S., Urba, W.J., Steinberg, S.M., Sundeen, J.T., Cossman, J., Young, R.C., Glatstein, E.: Retrospective analysis of Stage I and II indolent lymphomas at the National Cancer Institute. Int. J. Radiat. Oncol. Biol. Phys. 14:417-424, 1988.

  20. Steis, R.G., Marcon, L., Clark, J., Urba, W.J., Longo, D.L., Nelson, D.L., Maluish, A.E.: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 71:1304-1309, 1988.

  21. Urba, W.J., Longo, D.L., Lombardo, F.A., Weiss, R.B.: Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J. Natl. Cancer Inst. 80:521-525, 1988.

  22. Steis, R.G., Smith, J.W., Urba, W., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C., Longo, D.L.: Resistance to recombinant interferon alfa 2A in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409-1413, 1988.

  23. Chmurny, G.N., Mellini, M.L., Halverson, D., Issaq, H.J., Muschik, G.M., Urba, W.J., McGregor, G.N., Hilton, B.D.: A comparison of high performance gel permeation chromatography and nuclear magnetic reson¬ance spectroscopy in the analysis of plasma from normal subjects and cancer patients. J. Liq. Chromatog. 11:647-664, 1988. BIBLIOGRAPHY (CONT):

  24. Wilding, G.W., Greene, H.L., Longo, D.L., Urba, W.J.: Tumors of the heart and pericardium. Cancer Treat. Rev. 15(3):165-181, 1988.

  25. Hornung, R.L., Back, T.C., Zaharko, D.S., Urba, W.J., Longo, D.L., Wiltrout, R.H.: Augmentation of natural killer activity, induction of interferon and development of tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid (FAA) and interleukin-2. J. Immunol. 141:3671-3679, 1988.

  26. Spector, N.L., Samson, W., Ryan, C., Gribben, J., Urba, W.J., Welch, W.J., Nadler, L.M.: Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28). J. Immunol. 148:1668-1673, 1992.

  27. Hornung, R.L., Young, H., Urba, W.J., Wiltrout, R.H.: Immunomodula¬tion of natural killer cell activity by flavone acetic acid: occur¬rence via induction of IFN-?. J. Natl. Cancer Inst. 80(15): 1226-1231, 1988.

  28. Chmurny, G.N., Hilton, B.D., Halverson, D., McGregor, G.N., Klose, J., Issaq, H.J., Muschik, G.M., Urba, W.J., Mellini, M.L., Costello, R., Papadopoulos, N.M., Caporaso, N.: An NMR blood test for cancer: A critical assessment. NMR Biomedicine 1:136-150, 1988.

  29. Giardina, S.L., Young, H.W., Faltynek, C.R., Jaffe, E.S., Clark, J.W., Steis, R.G., Urba, W.J., Mathieson, B.J., Gralnick, H., Lawrence, J., Overton, W.R., Longo, D.: Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patients resistant to interferon-alpha. Blood 72(5): 1708-1716, 1988.

  30. Urba, W.J., Baseler, M.W., Kopp, W.C., Steis, R.G., Clark, J.W., Smith II, J.W., Coggin, D.L., Longo, D.L.: Deoxycoformycin-induced immuno¬suppression in patients with hairy cell leukemia. Blood 73(1): 38-46, 1989.

  31. Longo, D.L., Urba, W.J.: Hodgkin's disease. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1191-1195, 1989.

  32. Urba, W.J., Longo, D.L.: Lymphocytic lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1195-1202, 1989.

  33. Longo, D.L., Urba, W.J.: Differential diagnosis of lymphadenopathy and approach to the management lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medi¬cine. Philadelphia, J.B. Lippincott Company, 1311-1323, 1989.

  34. Urba, W.J., Longo, D.L.: Diffuse aggressive lymphoma in adults. In Magrath, I (Ed.): New Directions in Cancer Treatment. Geneva, Springer-Verlag Publishers, 575-579, 1989.

  35. Urba, W.J., Baseler, M.W.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/10. Amsterdam, Elsevier Science Publishers B.V., 473-491, 1989.

  36. Miller, R.L., Steis, R.G., Clark, J.W., Smith II, J.W., Crum, E., McKnight, J.E., Hawkins, M.J., Jones, M.J., Longo, D.L., Urba, W.J.: Randomized trial of recombinant interferon alfa-2b with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49: 1871-1876, 1989.

  37. Urba, W.J., Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/10. Amsterdam, Elsevier Science Publishers B.V., 460-472, 1988.

  38. Urba, W.J., Clark, J.W., Steis, R.G., Bookman, M.A., Smith II, J.W., Beckner, S., Maluish, A.E., Rossio, J.L., Rager, H., Ortaldo, J.R., Longo, D.L.: Intraperitoneal lymphokine-activated killer cell/interleukin 2 therapy in patients with intra-abdominal cancer: immunologic considerations. J. Natl. Cancer. Inst. 81(8): 602-611, 1989.

  39. Schiogolev, S.A., Goetzl, E.J., Urba, W.J., Longo, D.L.: Appearance of neuropeptides in ascitic fluid after intraperitoneal therapy with interleukin 2 and lymphokine-activated killer cells for intraabdominal malignancy. J. Clin. Immunol. 9(2): 169-173, 1989.

  40. VanderMolen, L.A., Urba, W.J., Longo, D.L., Lawrence, J., Gralnick, H., Steis, R.G.: Diffuse osteosclerosis in hairy cell leukemia. Blood 74(6): 2066-2069, 1989.

  41. Hartmann, L.C., Urba, W.J., Steis, R.G., Smith II, J.W., VanderMolen, L.A., Creekmore, S.P., Sznol, M., Casciano, M.A., Engler, N., Longo, D.L.: Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2 treated patients. J. Natl. Cancer Inst. 81:1190-1193, 1989.

  42. Steis, R.G., Clark, J., Longo, D.L., Smith, J., Miller, R., Ruscetti, F., Hursey, J., Urba, W.: A phase Ib evaluation of recombinant human granulocyte-macrophage colony-stimulating factor. In Beger, H.G., Buchler, M., Reisfeld, R.A., Schulz, G. (Eds.): Cancer Therapy: Monoclonal Antibodies, Lymphokines. Berlin, Springer-Verlag Publishing Co., 103-111, 1989.

  43. Hartmann, L.C., Urba, W.J., Steis, R.G., Smith II, J.W., VanderMolen, L., Creekmore, S.P., Longo, D.L.: Hypothyroidism after interleukin-2 therapy. J. Clin. Oncol. 7:686-687, 1989.

  44. Beckwith, M., Longo, D.L., O'Connell, C.D., Moratz, C.M., Urba, W.J.: Phorbol ester-induced, cell-cycle specific, growth inhibition of human B-lymphoma cell lines. J. Natl. Cancer Inst. 82(6): 501-509, 1990.

  45. Martin, A., Nerenstone, S., Urba, W.J., Longo, D.L., Lawrence, J.B., Clark, J.W., Hawkins, M.J., Creekmore, S.P., Smith, J.W., Steis, R.G.: Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: Results of a phase II study. J. Clin. Oncol. 8:721-730, 1990.

  46. Urba, W.J., Duffey, P.L., Longo, D.L.: Treatment of patients with aggressive lymphomas: an overview. J. Natl. Cancer Inst. Monogr. 10:29-37, 1990.

  47. Creekmore, S.P., Longo, D.L., Urba, W.J.: The development of regimens for combination immunotherapy. In Rees, R.C. (Ed.) The Biology and Clinical Applications of Interleukin-2. New York, Oxford University Press, 98-110. 1990.

  48. Urba, W.J., Baseler, M.W.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Chabner, B.A., Longo, D.L., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/11. Amsterdam, Elsevier Science Publishers, 281-302, 1990.

  49. Steis, R.G., Urba, W.J., Vandermolen, L.A., Bookman, M.A., Smith II, J.W., Clark, J.W., Miller, R.L., Crum, E.D., Beckner, S.K., McKnight, J.E.: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin. Oncol. 8(10): 1618-1629, 1990.

  50. Urba, W.J., Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Chabner, B.A., Longo, D.L., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/11. Amsterdam, Elsevier Science Publishers B.V., 265-280, 1990.

  51. Steis, R.G., VanderMolen, L.A., Longo, D.L., Clark, J.W., Smith II, J.W., Kopp, W.C., Ruscetti, F.W., Creekmore, S.P., Elwood, L.J., Hursey, J., Urba, W.J.: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase Ib trial. J. Natl. Cancer Inst. 82: 697-703, 1990.

  52. Steis, R.G., Carrasquillo, J.A., Clark, J.W., Bookman, M.A., Reynolds, J.C., Larson, S., Smith II, J.W., Dailey, V., Del Vecchio, S., Shuke, N., Pinsky, C.M., Urba, W.J., Haspel, M., Perentesis, P., Paris, B., Longo, D.L., Hanna, M.G.: Toxicity, immuno¬genicity, and tumor radioimmunodetecting ability of two human mono¬clonal antibodies in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 8:476-490, 1990.

  53. Urba, W.J., Steis, R.G., Longo, D.L., Kopp, W.C., Maluish, A.E., Marcon, L., Nelson, D.L., Stevenson, H.C., Clark, J.W.: Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 50:185-192, 1990.

  54. VanderMolen, L.A., Steis, R.G., Duffey, P.L., Foon, K.A., Smith II, J.W., Clark, J.W., Conlon, K., Stevenson, H.C., Urba, W.J., Hartmann, L.C., Watson, T., Jaffe, E.S., Longo, D.L.: Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 82:235-238, 1990.

  55. Steis, R.G., VanderMolen, L.A., Lawrence, J., Sing, G., Ruscetti, F., Smith II, J.W., Urba, W.J., Clark, J., Longo, D.L.: Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha. Br. J. Haematol. 75:1, 133-135, 1990.

  56. Urba, W.J., Hartmann, L.C., Longo, D.L., Steis, R.G., Smith II, J.W., Kedar, I., Creekmore, S., Sznol, M., Conlon, K., Kopp, W.C., Huber, C., Herold, M., Alvord, W.G., Snow, S., Clark, J.W.: Phase I and immuno¬modulatory study of a muramyl peptide, MTP-PE. Cancer Res. 50:2979-2986, 1990.

  57. Conlon, K.C., Urba, W.J., Smith, J.W., Steis, R.G., Longo, D.L., Clark, J.W.: Exacerbation of symptoms of autoimmune disease in patients receiving IFN-a therapy. Cancer 65:2237-2242, 1990.

  58. Sing, G.K., Ruscetti, F.W., Beckwith, M., Keller, J.R., Ellingsworth, L., Urba, W.J., Longo, D.L.: Growth inhibition of a human lymphoma cell line: Induction of a transforming growth factor-mediated autocrine negative loop by phorbol myristate acetate. Cell Growth & Differentiation 1:549-557, 1990.

  59. Clark, J.W., Smith II, J.W., Steis, R.G., Urba, W.J., Crum E., Miller, R., McKnight, J., Beman, J., Stevenson, H.C., Creekmore, S., Stewart, M., Conlon, K., Sznol, M., Kremers, P., Cohen, P., Longo, D.L.: Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 50:7343-7350, 1990.

  60. Smith II, J., Urba, W., Steis, R., Janik, J., Sharfman, W., Conlon, K., Sznol, M., Creekmore, S., Wells, N., Elwood, L., Keller, J., Hestdal, K., Ewel, C., Rossio, J., Kopp, W., Shimuzu, M., Oppenheim, J., Longo, D.L.: A phase I trial of interleukin-1 alpha (IL-1 ) alone and in combination with indomethacin. Lymphokine Res. 9:568, 1990.

  61. Urba, W.J., Longo, D.L.: Lymphocytic lymphomas: Epidemiology, etiology, pathology and staging. In Moossa, A.R., Schimpff, S.C., and Robson, M.C. (Eds.): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1268-1276, 1991.

  62. Steis, R.G., Smith II, J.W., Urba, W.J., Venzon, D.J., Longo, D.L., Barney, R., Evans, L.M., Itri, L.M., Ewel, C.H.: Loss of interferon antibodies during prolonged continuous interferon- 2a therapy in hairy cell leukemia. Blood 77(4): 792-798, 1991.

  63. Sznol, M., Urba, W.J.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/12. Amsterdam, Elsevier Science Publishers, 213-230, 1991.

  64. Longo, D.L., Glatstein, E., Duffey, P.L., Young, R.C., Hubbard, S.M., Urba, W.J., Wesley, M.N., Raubitschek, A., Jaffe, E.S., Wiernik, P.H., DeVita, Jr., V.T.: Radiation therapy vs. combination chemotherapy in the treatment of early stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J. Clin. Oncol. 9: 906-917, 1991.

  65. Urba, W.J., Longo, D.L.: Lymphocytic lymphoma: clinical course and management. In Moossa, A.R., Schimpff, S.C., Robson, M.C. (Eds): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1277-1295, 1991.

  66. Loeffler, C.M., Platt, J.L., Anderson, P.M., Katsanis, E., Ochoa, J.B., Urba, W.J., Longo, D.L., Leonard, A.S., Ochoa, A.C.: Antitumor effects of Interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res. 51: 2127-2132, 1991.

  67. Urba, W.J., Longo, D.: Burkitt's lymphoma. In Moossa, A.R., Schimpff, S.C., Robson, M.C. (Eds.): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1296-1301, 1991.

  68. Smith, J.W., II, Urba, W.J., Steis, R.G., Sznol, M., Longo, D.L.: Clinical trials of selected interleukins: the Biological Response Modifiers Program experience. In Denman, A.M., Baxter, A. (Eds.): British Society for Immunology Jenner Symposium "Cytokine Interaction and Control". Sussex, J. Wiley & Sons Ltd., 177-194, 1991.

  69. Baseler, M.W., Urba, W.J.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/12. Amsterdam, Elsevier Science Publishers, 231-250, 1991.

  70. Creekmore, S.P., Urba, W.J., Longo, D.L.: Principles of the clinical evaluation of biological agents. In DeVita, V.T., Jr., Hellman, S., Rosenberg, S.A. (Eds.): Biologic Therapy of Cancer. Philadelphia, J.B. Lippincott, 67-86, 1991.

  71. Urba, W.J., Kopp, W.C., Clark, J.W., Smith II, J.W., Steis, R.G., Huber, C., Coggin, D., Longo, D.L.: The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor. J. Clin. Oncol. 9:1831-1839, 1991.

  72. Smith II, J.W., Urba, W.J., Clark, J.W., Longo, D.L., Farrell, M., Creekmore, S.P., Conlon, K.C., Jaffe, H., and Steis, R.G.: Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon gamma. J. Immunother. 10:355-362, 1991.

  73. Smith II, J.W., Longo, D.L., Urba, W.J., Clark, J.W., Watson, T., Beveridge, J., Conlon, K.C., Sznol, M., Creekmore, S.P., Alvord, W.G., Lawrence, J.B., and Steis, R.G.: Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon alfa-2a. Blood 78:1664-1671, 1991.

  74. Steis, R.G., Urba, W.J., Kopp, W.C., Alvord, W.G., Smith II, J.W. and Longo, D.L.: Kinetics of recovery of CD4+ T cells in the peripheral blood of deoxycoformycin-treated patients. J. Natl. Cancer Inst. 83:1678-1679, 1991.

  75. Tura, S., Canellos, G., Goldstone, A., Longo, D., McMillan, A., Urba, W., Zinzani, P.L.: Hodgkin's Disease: Controversies and challenges for the future. Haematologica 76:263-279, 1991.

  76. Beckwith, M., Urba, W.J., Ferris, D.K., Freter, C.E., Kuhns, D.E., Moratz, C.M., Longo, D.L.: Anti-IgM-mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation. J. Immunol. 147:2411-2418, 1991.

  77. Longo, D.L., Urba, W.J.: Hodgkin's disease. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, 2nd edition. Philadelphia, J.B. Lippincott Company, 1092-1096, 1992.

  78. Urba, W.J., Longo, D.L.: Lymphocytic lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, 2nd edition. Philadelphia, J.B. Lippincott Company, 1096-1102, 1992.

  79. Longo, D.L., Urba, W.J.: Approach to the management of disorders of the spleen. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, 2nd edition. Philadelphia, J.B. Lippincott Company, 1185-1189, 1992.

  80. Longo, D.L., Urba, W.J.: Differential Diagnosis of Lymphadenopathy and Approach to the Management of Lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, 2nd edition. Philadelphia, J.B. Lippincott Company, 1189-1200, 1992.

  81. Creekmore, S.P, Urba, W.J., Longo, D.L.: Strategies of Clinical Monitoring of Therapeutic Trials. In Noel R. Rose, et al. (Eds.): Manual of Clinical Laboratory Immunology, Fourth Edition, Washington, D.C., American Society of Microbiology, 915-922, 1992.

  82. Urba, W.J. and Longo, D.L.: Hodgkin's disease. N. Engl. J. Med. 326:678-687, 1992.

  83. Longo, D.L., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., Phares, J.C., Jaffe, E.S., Urba, W.J., DeVita Jr, V.T.,: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol. 10:210-218, 1992.

  84. Urba, W.J., Wilson, W.H., Duffey, P.L., Wittes, R., Chabner, B.A., Longo, D.L.: Recent NCI lymphoma trials of etoposide-containing combination chemotherapy. Semin. Oncol. 19 (Suppl.13):26-32, 1992.

  85. Ochoa, J.B., Curti, B., Peitzman, A.B., Simmons, R.L., Billiar, T.R., Hoffman, R., Rault, R., Longo, D.L., Urba, W.J., Ochoa, A.C.: Increased circulating nitrogen oxides after human tumor immunotherapy correlate with toxic hemodynamic changes. J. Natl. Cancer Inst. 84:864-867, 1992.

  86. Urba, W.J., Ewel, C., Kopp, W.C., Smith II, J.W., Steis, R.G., Ashwell, J.D., Creekmore, S.P., Rossio, J., Sznol, M., Sharfman, W., Fenton, R., Janik, J., Watson, T., Beveridge, J., Longo, D.L. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: A phase IA/B study. Cancer Res. 52:2394-2401, 1992.

  87. Ewel, C.H., Urba, W.J., Kopp, W.C., Smith II, J.W., Steis, R.G., Rossio, J.L., Longo, D.L., Jones, M.J., Alvord, W.G., Pinsky, C.M., Beveridge, J.M., McNitt, K.L., Creekmore, S.P.: Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: Clinical and immunologic effects. Cancer Res. 52:3005-3010, 1992.

  88. Spector, N.L., Samson, W., Ryan, C., Gribben, J., Urba, W.J., Welch, W.J., Nadler, L.M.: Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28). J. Immunol. 148:1668-1673, 1992.

  89. Sznol, M., Clark, J.W., Smith II, J.W., Steis, R.G., Urba, W.J., Rubinstein, L.V., VanderMolen, L.A., Janik, J., Sharfman, W.H., Fenton, R.G., Creekmore, S.P., Kramers, P., Conlon, K., Hursey, J., Beveridge, J., Longo, D.L.: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. Cancer Inst. 84:929-937, 1992.

  90. Loeffler, C.M., Smyth, M.J., Longo, D.L., Kopp, W.C., Harvey, L.K., Tribble, H.R., Tase, J.E., Urba, W.J., Leonard, A.S., Young H.A., Ochoa, A.C.: Immunoregulation in cancer-bearing hosts: down-regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol. 149:949-956, 1992.

  91. Smith II, J.W., Urba, W.J., Curti, B.D., Elwood, L.J., Steis, R.G., Janik, J.E., Sharfman, W.H., Miller, L.L., Fenton, R.G., Conlon, K.C., Sznol, M., Miller, L., Creekmore, S.P., Wells, N., Ruscetti, F.W., Keller, J.R., Hestdal, K., Shimizu, M., Alvord, W.G., Rossio, J., Oppenheim, J.J., Longo, D.L.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10:1141-1152, 1992.

  92. Sznol, M., Steis, R.G., Smith II, J.W., Janik, J.E., Sharfman, W.H., Urba, W.J., Fenton, R.G., Creekmore, S.P., Beveridge, J., Longo, D.L.: Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2A in patients with metastatic melanoma. Online J. Current Clin. Trials 1: 1992.

  93. Conlon, K.C., Ochoa, A.C., Kopp, W.C., Ortaldo, J.R., Urba, W.J., Longo, D.L., Young, H.A.: Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes. J. Immunol. 149:3278-3289, 1992.

  94. Sznol, M., Urba, W.J.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/13. Amsterdam, Elsevier Science Publishers, 192-204, 1992.

  95. Baseler, M.W., Urba, W.J.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/13. Amsterdam, Elsevier Science Publishers, 205-229, 1992.

  96. Urba, W.J.: Local-regional administration of IL2/LAK cells. In Atkins, M.B., Mier, J.W., (Eds.): Therapeutic Applications of Interleukin-2. New York, Marcel Dekker, 189-216, 1993.

  97. Kopp, W.C, Smith, II, J.W., Ewel, C.H., Alvord, W.G., Main, C., Guyre, P.M, Steis, R.G., Longo, D.L., Urba, W.J.: Immunomodulatory effects of interferon gamma (IFN-?) in patients with metastatic malignant melanoma. J. Immunother. 13:181-190, 1993.

  98. Janik, J., Kopp, W.C., Smith II, J.W., Longo, D.L., Alvord, W. G., Sharfman, W., Fenton, R., Sznol, M., Steis, R.G., Ewel, C., Hursey J., Urba, W.J.: Dose-related immunologic effects of levamisole in patients with cancer. J. Clin. Oncol. 11:125-135, 1993.

  99. Curti, B.D., Longo, D.L., Ochoa, A., Conlon, K. C, Smith II, J.W., Alvord, W.G., Creekmore, S.P., Fenton, R.G., Gause, B.L., Holmlund, J., Janik, J.E., Ochoa, J., Rice, P.A., Sharfman, W.H., Sznol, M., Urba, W.J.: Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J. Clin. Oncol. 11:652-660, 1993.

  100. Smith II, J.W., Longo, D.L., Alvord, W.G., Janik, J.E., Sharfman, W.H., Gause, B., Curti, B., Creekmore, S., Holmlund, J., Fenton, R.G., Sznol, M., Miller, L., Shimizu, M., Oppenheim, J.J., Feim, S., Hursey, J., Powers, G., Urba, W.J.: The effects of treatment with interleukin-1a on platelet recovery after high-dose carboplatin. N. Engl. J. Med. 328: 756-761, 1993.

  101. Beckwith, M., Urba, W.J., Longo, D.L.: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst. 85 (6): 483-488, 1993.

  102. Sznol, M. Urba, W.J.: Adoptive Cellular Therapy. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/14. Amsterdam, Elsevier Science Publishers, 227-248, 1993.

  103. Baseler, M.W., Kopp, W.C., Urba, W.J.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/14. Amsterdam, Elsevier Science Publishers, 245-283, 1993.

  104. Urba, W.J., Longo, D.L.: Hodgkin's disease in adults: Part I. Invest. Radiol., 28 (8):737-52, 1993.

  105. Urba, W.J. and Longo, D.L.: Hodgkin's disease in adults: Part II. Invest. Radiol., 28 (9):848-59, 1993.

  106. Longo, D.L., DeVita, Jr., V.T., Jaffe, E.S., Mauch, P., Urba, W.J.: Lymphocytic lymphomas. In DeVita, V.T., Hellman, S., Rosenberg, S.A., (Eds.): Cancer: Principles & Practice of Oncology, Fourth Edition. Philadelphia, J.B. Lippincott Co., 1859-1927, 1993.

  107. Creekmore, S.P., Reynolds, C.W., Hecht, T.T., Urba, W.J., Longo, D.L.: IL-2 therapy in human cancer. In Oppenheim, J., Rossio, J., and Gearing, A. (Eds.): Clinical Application of Cytokines: Role in Pathogenesis, Diagnosis, and Theory. New York, Oxford University Press, 147-154, 1993.

  108. Curti, B.D., Urba, W.J., Alvord, W.G., Janik, J.E., Smith II, J.W., Madera, K., Longo, D.L.: Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment. Cancer Res. 53 (10 Suppl.): 2204-7, 1993.

  109. Smith, J.W. Urba, W.J.: Evaluation of interleukin-1 as an anticancer agent. In Oppenheim, J., Rossio, J., Gearing, A. (Eds.): Clinical Application of Cytokines: Role in Pathogenesis, Diagnosis, and Theory. New York, Oxford University Press Publishers, 1993.

  110. Janik, J., Kopp, W.C., Smith II, J.W., Longo, D.L., Alvord, W.G., Urba, W.J.: Levamisole-induced neopterin synthesis. Immunomodulating Drugs, Annals of the New York Academy of Sciences, Vol. 685: 252-258, 1993.

  111. Janik, J., Sznol, M., Urba, W.J., Figlin, R., Bukowski, R.M., Fyfe, G., Pierce, W.C., Belldegrun, A., Sharfman, W.H., Smith II, J.W. Longo, D.L. Erythropoietin production: A potential marker for interleukin-2/interferon-responsive tumors. Cancer 72 (9): 2656-2659, 1993.

  112. Ochoa, A.C., Curti, B.D., Zea, A.H., Anderson, P.M., Saxton, M., Strobl, S.S., Kopp, W.C., Urba, W.J., Long, D.L.: Anti-CD3-stimulated T cells and IL-2 liposomes in adoptive immunotherapy. In Chang, A. E. and Shu, S. (Eds): Immunology of Cancer with Sensitized T Lymphocytes. R.G. Landes Co. Publishers, 1994.

  113. Sznol, M. and Urba, W.J.: Adoptive immunotherapy. In Pinedo, H.M., Longo, D.L., and Chabner, B.A., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual/15. Amsterdam, Elsevier Science Publishers, 1994.

  114. Kopp, W.C., Holmlund, J.T., Urba, W.J.: Immunological monitoring and clinical trials of biological response modifiers. In Pinedo, H.M., Longo, D.L., Chabner, B.A., (Eds): Cancer Chemotherapy and Biological Response Modifiers Annual/15. Amsterdam, Elsevier Science Publishers, 1994.

  115. Holmlund, J.T., Kopp, W.C., Wiltrout, R.M., Longo, D.L., Urba, W.J., Janik, J.E., Sznol, M., Conlon, K.C., Fenton, R.G., Hornung, R., Madara, K., Shields, M.A., Smith II, J.W., Sharfman, W., Steis, R.G., Ewel, C., Malspeis, L. Creekmore, S.P.: A phase I clinical trial of flavone-8-acetic acid (FAA) in combination with interleukin-2 (IL-2). J. Nat'l Cancer Inst., 87 (2): 134-136, 1995.

  116. Kwak, L.W., Grossbard, M. L., Urba, W.J.: Clinical applications of monoclonal antibodies in cancer: B-cell lymphomas. In DeVita, V.T., Hellman, S., Rosenberg, S.A., (Eds): Biological Therapy of Cancer. J. B. Lipincott Publishers, 1995.

  117. Beckwith, M., Ruscetti, F.W., Sing, G., Urba, W.J., and Longo, D.L.: Anti-IGM induces TGF- sensitivity in a human B-lymphoma cell line: Inhibition of growth involves down-regulation of mutant P53. Blood, 85 (9): 2461-2470, 1995.

  118. Urba, W.J., Ruscetti, F.W., Clark, J.W.: Adult T-cell lymphoma/ leukemia. In Abeloff, M., Armitage, J., Lichter, A., & Niederhuber, J., (Eds): Clinical Oncology. 1995.

  119. Zea, A.H., Curti, B.Dl, Longo, D. L., Alvord, W. G., Strobl, S.L., Mizoguchi, H., Creekmore, S., O'Shea, J.J., Powers, G. C., Urba, W. J., and Ochoa, A.C.: Alterations in T cell receptor and signal transduction in melanoma patients. Clin. Cancer Res. 1:1327-1335, 1995.

  120. Sharfman, W.H., Urba, W.J., Smith II, J.W., Janik, J.E., Curti, B.D., Gause, B.L., Holmlund, J.T., Steis, R.G., Beauchamp, A.E. and Longo, D.L.: Phase I/II trial of 5-fluorouracil, leucovorin, zidovudine, and dipyridamole for patients with metastatic colorectal cancer, renal cell carcinoma, and malignant melanoma. Int. J. Oncol. 6:579-583, 1995.

  121. Janik, J.E., Miller, L.L., Longo, D.L., Powers, G.C., Gause, B.L., Curti, B.D., Steis, R.G., Oppenheim, J.J., Conlon, K.C., Sznol, M., Holmlund, J.T., Creekmore, S.P., Beauchamp, A.E., Smith II, J.W. and Urba, W.J.: Phase II trial of interleukin-1 and indomethacin in the treatment of metastatic melanoma. J. Nat'l Cancer Inst. 88 (1): 44-49, 1996.

  122. Fidias, P., Wright, C., Harris, N.L., Urba, W., Grossbard, M.L.: Primary tracheal non-hodgkin's lymphoma: A case report and review of the literature of tracheobronchial lymphoma. Cancer 7(11), 232-2338, 1996.

  123. Curti, B., Urba, W.J., Longo, D.L., Janik, J.E., Sharfman, W.H., Miller, L.L., Cizza, G., Shimizu, M., Oppenheim, J.J., Alvord, W. G., Smith II, J.W.: Endocrine effects of IL-1a and ß administered in a phase I trial to patients with advanced cancer. J. Immunother. 19(2):142-148, 1996.

  124. Gause, B.L., Sznol, M., Kopp, W.C., Janik, J.E., Smith II, J.W., Steis, R.G., Urba, W.J., Sharfman, W., Fenton, R.G., Creekmore, S.P., Holmlund, J., Conlon, K.C., VanderMolen, L.A. & Longo, D.L.: Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a inpatients with advanced cancer. J. Clin. Oncol. 14(8): 2234-2241, 1996.

  125. Fenton, R.G., Steis, R.G., Medera, K., Janik, J.E., Smith II, J.W., Gause, B.L., Sharfman, W.H., Urba, W.J., Hanna, M.G., DeJager, R.L., Coyne, M.X., Crouch, R.D., Creekmore, S.P., Holmlund, J., Conlon, K., Curti, B.D., Sznol, M., Longo, D.L.: A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J. Immunother. 19:364-74, 1996.

  126. Kopp, W.C., Urba, W.J., Rager, H.C., Alvord, W.G., Oppenheim, J.J., Smith II, J.W., Longo, D.L.: Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin. Cancer Res. 2:501-6, 1996.

  127. Curti, B.D., Ochoa, A.C., Urba, W.J., Alvord, G., Kopp, W.C., Powers, G., Hawk, C., Creekmore, S.P., Gause, B.L., Janik, J.E., Holmlund, J.T., Fenton, R.G., Sznol, M., Smith II, J.W., Sharfman, W.H. and Longo, D.L.: The influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients. J. Immunother. 14(4):296-308, 1996.

  128. Urba, W.J. and Chabner, B.: Principles of biologic therapy. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, 3rd edition. Philadelphia, J.B. Lippincott Company, 1997, 1519-1522.

  129. Seiden, M., Urba, W.J. & Chabner, B.A.: Principles of chemotherapy and hormone therapy. In Kelley, R.N. (Ed) Textbook of Internal Medicine, 3rd edition. Philadelphia, J.B. Lippincott Company, 1997.

  130. Gause, B.L., Sharfman, W.H., Janik, J.E., Curti, B.D., Steis, R.G., Urba, W.J., Smith II, J.W. & Longo, D.L.: A phase II study of carboplatin, cisplatin, interferon-a and tamoxifen for patients with metastatic melanoma. Cancer Invest. 16(6), 374-380, 1998.

  131. Fox, B.A., Drury, M., Hu, H-M, Cao, Z., Huntzicker, E.G., Qie, W., Urba, W.J.: Lipofection indirectly increases expression of endogenous major histocompatability complex class I molecules on tumor cells. Cancer Gene Ther. 5(2), 1998.

  132. Lenz, K., Rowinsky, E. K., Urba, W. J.: Advances in chemotherapy. Pat. Care 32 (4), 42-61, 1998.

  133. Hainsworth, J.D., Urba, W.J., Hon, J.K., Thompson, K.A., Stagg, M.P., Hopkins, L.G., Thomas, M. Greco, F.A.: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, phase II trial. Eur. J. Cancer 34 (5), 654-658, 1998.

  134. Hu, H-M, Urba, W.J., Fox, B. A.: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile. J. Immunol. 161(6): 3033-41, 1998.

  135. Kurt, R.A., Urba, W.J., Smith II, J.W., and Schoof, D.D.: Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int'l. J. Cancer, 78 (1): 16-20, 1998.

  136. Schoof, D.D., Smith II, J.W., Disis, M.L., Brant-Zawadski, P., Wood, W., Doran, T., Johnson, E., Urba, W.J.: In: Walden et al (Eds.) Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Gene Therapy of Cancer. Plenum Press, NY, 1998.

  137. Schoof, D.D., Smith II, J.W., Disis, ,M.L., Brant-Zawadski, P., Wood, W., Doran, T., Johnson, E., Urba, W.J.: Immunization of Metastatic Breast Cancer Patients with CD80-Modified Breast Cancer Cells and GM-CSF. Adv. Exp. Med. Biol., 451:511-8, 1998.

  138. Chu, Y., Hu, H-M, Winter, H., Wood, W.J., Doran, T., Lashley, D. Bashey, J., Schuster, J., Wood, J., Lowe, B.A., Vetto, J.T., Weinberg, A.D., Puri, R., Smith II, J.W., Urba, W.J. and Fox, B.A.: Examining the immune response in sentinel lymph nodes of mice and men. Eur. J. Nucl. Med., 26 (4 Suppl.), S50-3, 1999.

  139. Miller, L.L., Korn, E.L., Stevens, D.S., Janik, J.E., Gause, B.L., Kopp, W.C., Holmlund, J.T., Curti, B. D., Sznol, M., Smith II, J.W., Urba, J.W., Donegan, S.E., Watson, T.M., Garrison, L., Hanna, R. and Longo, D.L.: Abrogation of the hematological and biological activities of the interleuken-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood, 93 (10): 3250-58, 1999.

  140. Margolin, K.A., Liu, P.Y., Unger, J.M., Fletcher, W.S., Flaherty, L.E., Urba, W.J., Hersh, E.M., Hutchins, L.F., Sosman, J.A., Smith II, J.W., Weiss, G.R., Sondak,, V.K.: Phase II trial of biochemotherapy with a-IFN, DTIC, CDDP and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. J. Cancer Res. Clin. Oncol., 125 (5): 292-6, 1999.

  141. Choudhary, A., Kurt, R. A., Goret, F., Moreau, A., Diez, E., Urba, W.J., Jotereau, F and Pourcel, C.: Mutated cytochrome B as a determinant of a new monoclonal antibody (H8.98) on renal carcinoma cell lines recognized by a V?Vd1+ T cell clone. Int. J. Cancer, 82(4): 562-8, 1999.

  142. Winter, H., Hu, H-.M, Urba, W.J., Fox, B.A.: Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol., 163 (8): 4462-72, 1999.

  143. Ozols, R., (Editor in Chief), Urba, W.J. (Assoc. Ed, et al: Year Book of Oncology (1999). St. Louis, Mosby-Year Book, Inc. Publisher, 2000.

  144. Kurt, R.A., Urba, W.J., Schoof, D.D.: Isolation of genes over expressed in freshly isolated breast cancer specimens. Breast Cancer Res and Treatment, 59: 41-48, 2000.

  145. Weinberg, A.D., Rivera, M-M, Prell, R., Morris, A., Ramstad, T., Vetto, J.T., Urba, W.J., Alvord, W.G., Bunce, C and Shields, J.: Engagement of the OX-40 Receptor in vivo enhances anti-tumor immunity. J. Immunol., 164(4):2160-9, 2000.

  146. Longo, D.L., Duffey, P.L., Gribben, J.G., Jaffe, E.S., Curti, B. D., Gause, B.L., Janik, J.E., Bramen, V.M., Esseltine, D., Wilson, W.H., Kaufman, D., Wittes, R.E., Nadler, L. M., Urba, W.J.: Combination chemotherapy followed by a recombinant immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J. Sci.Am. May-June; 6(3): 146-50, 2000.

  147. Smith II, J.W. and Urba, W.J.: Principles of Biologic Therapy. In Humes et al (Eds.) Kelley's Textbook of Internal Medicine, 4th Edition. Philadelphia, Lippincott Williams and Wilkins Company, 2000.

  148. Hu, H-M, Winter, H., Urba, W. J., Fox, B. A.: Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol., Oct 15;165(8):4246-53, 2000.

  149. Kurt, R. A., Whitaker, R., Baher, A., Seung, S., Urba, W. J.: Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int. J. Cancer, Sep. 1: 87(5): 688-94, 2000.

  150. Kurt, R. A., Baher, A., Wisner, K. P., Tackitt, S., Urba, W. J.: Chemokine receptor desensitization in tumor-bearing mice. Cellular Immunol., 207: 81-88, 2001.

  151. Winter, H., Hu, H-M, McClain, K., Urba, W.J. and Fox, B.A.: Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol., 166(12): 7370-80, 2001.

  152. Meijer, S. L., Dols, A., Hu, H-M, Jensen, S., Poehlein, C. H., Chu, Y., Winter, H. Yamada, J., Moudgil, T., Wood, W. J., Doran, T., Justice, L., Fisher, B., Wisner, P., Wood, J., Vetto, J. T., Mehrotra, R., Rosenheim, S., Weinberg, A. D., Bright, R., Walker, E., Puri, R., Smith II, J. W., Urba, W. J. and Fox, B. A.: Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine development. J. Clin. Pharmacol., July Suppl, 81S-94S, 2001.

  153. Janik, J., Langdon, L., Miller, E.L., Korn, D. S., Curti, D. C., Smith II, J.W., Sznol, M., Conlon, K.C., Sharfman, W., Urba, W.J., Gause, B. L., and Longo, D. : A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naïve patients with malignant melanoma or renal cell carcinoma. Blood, 97: 1942-46, 2001.

  154. Kurt, R. A., Bauck, M., Harma, S., McCulloch, K., Baher, A., Urba, W. J.: Role of C chemokine lymphotactin in mediating recruitment of antigen-specific CD62L 1o cells in vitro and in vivo. Cell Immunol., 109(2):83-8, 2001.

  155. Urba, W.J., Alvord, W.G.: Are all hypotheses generated before data analysis prospective? J. Clin. Oncol. 20(6), 1431-1433, 2002.

  156. Meijer, S.L., Dols, A., Urba, W.J., Hu, H.-M., Smith, J.W. II, Vetto, J., Wood, W., Doran, T., Chu, Y., Sayaharuban, P., Alvord, W.G., and Fox, B.A.: Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes following vaccination with HLA-B7ß 2-microglobulin gene-modified autologous tumor cells. J. Immunother. 25:359-372.2002.

  157. Hu, H-M, Poehlein, C.H., Urba, W.J., and Fox, B.A.: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62:3914-1919,.2002.

  158. Hu, H-M, Winter, H., Ma, J., Croft, M., Urba, W.J., and Fox, B.A.: CD28, TNFR and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J. Immunol. 169: Nov 1, 2002.

  159. Ruettinger, D., Li, R., Urba, W.J., Fox, B.A., Hu, H-M: Evaluation of a preclinical model of bone metastasis for the study of adoptive immunotherapy. Eur. Surg. Res, 2003.

  160. Poehlein, C.H., Hu, H.M., Yamada, J., Assmann, I., Alvord, W.G., Urba, W.J. and Fox, B.A., TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol, 170(4): 2004-13, 2003.

  161. Dols, A., Meijer, S.L., Smith, II, J.W., Fox, B.A., Urba, W.J. Allogeneic breast cancer cell vaccines. Clin. Breast Cancer. 3 Suppl 4: S173-80, 2003.

  162. Kurt, R.A., Bauck, M., Harma, S., Adler, E., Vitiello, P., Wisner, K.P., Tackitt, S, Urba, W.J. Altered chemokine receptor sensitivity in fvbn202 rat neu transgenic mice. Breast Cancer Res. Treat. 77(3): 225-32, 2003.

  163. Dols, A, Meijer, S.L., Hu, H-M, Goodell, V., Disis, M.L., Von Mensdorff-Pouilly, S., Verheijen, R., Alvord, W.G., Smith II, J.W., Urba, W.J., Fox, B.A.: Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J. Immunother. 26(2): 163-70, 2003.

  164. Smith II, J.W., Kurt, R.A., Baher, A.G., Denman, S., Justice, L., Doran, T., Gilbert, M., Alvord, W.G., Urba, W.J.: Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient IL-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma. J. Immunother. 26(2): 130-8, 2003.

  165. Jensen, S.M., Meijer, S.L., Kurt, R.A., Urba, W.J., Hu, H-M, Fox, B.A.: Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J. Immunol. 170(4): 2014-21, 2003.

  166. Winter, H., Hu, H-.M, Poehlein, C.H., Huntzicker, E., Osterholzer, J.J., Bashy, J., Lashley, D., Lowe, B., Yamada, .J, Alvord, G., Urba, W.J., Fox, B.A.: Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. J. Immunol. 108(3): 409-19, 2003.

  167. Smith II, J.W., Walker, E., Fox, B.A., Haley,D., Wisner, K.P., Doran, T., Fisher, B., Justice, L., Wood, W.J., Vetto, J.T., Dols, A., Meijer, S.L., Hu, H-M, Romero, P., Alvord, W.G., Urba, W.J.: Adjuvant immunization of HLA-A2+ melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T cell responses. J. Clin. Oncol, 21(8), 2003.

  168. Clark, J.I., Atkins, M.B., Urba, W.J., Creech, S., Figlin, R.A., Dutcher, J.P., Flaherty, L. , Sosman, J.A., Logan, T.F., White, R., Weiss, G.R., Redman, B.G., Tretter, C.P., McDermott, D., Smith II, J.W., Gordon, M.S. and Margolin, K.A. Adjuvant high-dose bolus Interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized Trial. J. Clin Oncol, 2003.

  169. Ma, J., Urba, W.J., Si, L., Wang, Y., Fox, B.A., Hu, H-M, Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur. J. Immunol, 33 (8): 2123-2132, 2003.

  170. Dols, A., Smith II, J.W., Meijer, S.L., Fox B.A., Hu, H-M, Walker, E., Rosenheim, S., Moudgil, T., Doran, T., Wood, W., Seligman, M., Alvord, W.G., Schoof, D. and Urba, W.J.: Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results. Hum. Gene Ther., 14: 1117-1123, 2003.

  171. Hu, H-M, Dols, A., Meijer S.L., Floyd, K., Walker, E., Urba, W.J., and Fox, B.A.: Immunological monitoring of peptide vaccination in melanoma patients using soluble peptide/HLA-A2 dimer complexes. J. Immunother.27 (1): 48-59, 2004.

  172. Walker, E.B., Haley, D., Miller, W., Floyd, K., Wisner, K.P., Maecker, H., Romero, P., Hu, H-M, Alvord, W.G., Smith II, J.W., Fox, B.A., Urba, W.J.: gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin. Cancer Res.,10: 668-680, 2004.

  173. Li, R., Urba, W.J., Fox, B.A., Hu, H-M: Targeting and amplification of immune killing of tumor cells by pro-Smac. Int. J. Cancer, 109, 85-94, 2004.

  174. Ma, J., Poehlein, C.H., Jensen, S.M., LaCelle, M.G., Moudgil, T.M., Ruttinger, D., Haley, D., Goldstein, M.J., Smith II, J.W., Curti, B., Ross, H., Walker, E., Hu, H-M, Urba, WJ, Fox, B.A.: Manipulating the host response to autologous tumour vaccines. Development of Therapeutic Cancer Vaccines. Dev. Biol. Basel, Karger, 116, 93-107, 2004.

  175. Meijer, S.L., Dols, A., Hu, H-M, Chu, Y., Romero, P., Urba, W.J., Fox, B.A. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol. 227, 93-102, 2004.

  176. McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M.S., Sosman, J.A., Ernstoff, M.S., Tretter, C.P., Urba, W. J., Smith, J.W., Margolin, K.A., Mier, J.W., Gollob, J.A., Dutcher, J.P. and Atkins, M.B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133, 2005.

  177. Hu, H.-M., Chu, Y. and Urba, W.J. Undefined-Antigen Vaccines. In Tumor Immunology and Cancer Vaccines. S. Khleif, ed. Kluwer Academic Publishers, New York, p. 207, 2005. Submitted for Publication: 1.

Submitted for Publication:
  1. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

INVITED LECTURES:

"The Role of Intraperitoneal IL2 and LAK Cells in the Management of Ovarian Cancer" at the Business Meeting Gynecologic Oncology Study Group. Miami, Florida. January 31, 1987.

"Biological Response Modifiers" at the City of Hope National Medical Center. Duarte, California. June 5, 1987.

"Biological Response Modifiers" at the Johns Hopkins Oncology Center's 14th Annual Symposium on Diagnosis and Treatment of Neoplastic Disorders, Johns Hopkins Medical Institute. Baltimore, Maryland. April 8, 1988.

"Clinical Evaluation of Interferon Gamma as a Biological Response Modifier" at the University of Texas Health Science Center. San Antonio, Texas. June 23, 1988.

"Hematopoietic Growth Factors as Protectors of Bone Marrow in Patients With Metastatic Cancer Treated With High Doses of Chemotherapy" at the National Institutes of Health, US-USSR Joint Cancer Treatment Projects. Bethesda, Maryland. September 7, 1988.

"The Biological Therapy of Melanoma", Medical Grand Rounds, St. Luke's Hospital. Kansas City, Missouri. July 14, 1989.

"Clinical Use of Biological Agents in Patients With Cancer" at the National Cancer Institute sponsored meeting, U.S. - Japan Cooperative Agreement. San Francisco, California. November 13-14, 1989.

"Biological Therapy", Human Cancer Colloquium at the University of Wisconsin Clinical Cancer Center. Madison, Wisconsin. May 10, 1989.

"Immunologic Effects of IL2 Administration" at the Sixth Annual NCI/EORTC Symposium. Amsterdam, The Netherlands. March 7-10, 1989.

"Biological Response Modifiers and Potential Application in Therapy of Malignant Melanoma" at the Oncology Update Program on Malignant Melanoma. St. Louis, Missouri. September 21, 1989.

"Results of a Phase I Clinical Trial Using Interleukin 1 alfa" at the Northeast Ohio Society of Clinical Oncology Annual Forum. Cleveland, Ohio. March 14, 1990.

"IL-2 in Patients With Malignant Lymphoma: US Experience" at the NCI-INSERM Workshop, The Use of IL-2 in Hematologic Malignancies. Bethesda, Maryland. September 12, 1991.

"Immunomodulation with Levamisole: Overview of Current Cancer Clinical Trials" at the Janssen Research Foundation Bio-Science Advisory Committee Meeting on New Developments in Cancer Therapy. The Institute of Physics, London, England. October 8, 1991.

"NCI Experience with Etoposide in Lymphomas" at the Bristol-Myers Oncology Division Symposium on Current Perspectives on the Use of Etoposide in Standard Doses. Boca Raton, Florida. December 6-7, 1991.

"Clinical Studies With IL-2 and Anti-CD3" at the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Free University of Amsterdam, The Netherlands. March 20, 1992.

"Clinical Development of Interleukin-1" at NIH Clinical Center Combined Rounds. Bethesda, Maryland. June 3, 1992.

"NCI Experience With Indolent Lymphomas" at the Georgia Oncology Hematology Clinic. Atlanta, Georgia. June 4, 1992.

"Biological Therapy of Melanoma at the Biological Response Modifiers Program" at the Baton Rouge Oncology Group. Baton Rouge, Louisiana. September 1, 1992.

"The NCI Approach to Low Grade Lymphomas" at Seminars in Oncology, Howard University Cancer Center. Washington, D.C. September 17, 1992.

"Chemotherapy for Non-Hodgkin's Lymphomas: The NCI Experience" at Searle Center for Continuing Education in the Health Sciences at Duke University Medical Center. Durham, North Carolina. October 16, 1992.

"Biological Response Modifiers" at the 8th Brazilian Congress of Clinical Oncology, Sao Paulo, Brazil. October 9-12, 1993.

"Recombinant Interleukin-1 in the Treatment of Neoplastic Disorders: The BRMP Experience" at the Cytokines in Haematology/Oncology Symposium. Vienna, Austria. June 1993.

Teaching Grand Rounds, Providence Portland Medical Center, Portland, Oregon, April 3-26, 1995.

"Follow-up for Patients with Breast Cancer: What's Appropriate?" an Internal Medicine Review Course, Providence Portland Medical Center, Portland, Oregon, April 7, 1995.

"Lung Cancer '95", Medical Grand Rounds, Providence Portland Medical Center, Portland, Oregon, May 3, 1995.

"New Healthcare Technologies: New Costs, New Standards, New Questions" at City Club of Portland, Portland, Oregon. September 14, 1995.

"Introduction to the diagnostic workup and staging of lymphomas", "Management of advanced stage, low grade and high grade non-Hodgkin's lymphomas" and "Issues in the chemotherapeutic management of advanced Hodgkin's disease" at the Fifth Annual Oregon Coast Oncology Conference, Coos Bay, Oregon. November 17, 1995.

"Immunotherapy and Clinical Trials" at Oncology Grand Rounds Program, Legacy Good Samaritan Hospital, Portland, Oregon. December 13, 1995.

"Current Research & Treatment Options for Advanced Breast Cancer - New Treatments" at Issues After Breast Cancer, Portland State University, Portland, Oregon. February 24, 1996.

"Advanced Breast Cancer Research Update", Issues after Breast Cancer Conference at PSU, April 26, 1997.

"Adjuvant Therapy of Melanoma and Chemotherapy of Metastatic Disease", invited lecture, Oregon Dermatology Society Melanoma Conference, Portland, OR, May 14, 1997.

"Hodgkin's Disease: The Price of Success", Medical Grand Rounds, Providence Portland Medical Center, August 27, 1997.

"Biological Therapy of Cancer", Hematology/Oncology presentation for Internal Medicine Residents, Providence Portland Medical Center, November 4, 1997.

"Biological Therapy of Cancer", American College of Physicians, Oregon Chapter Scientific Meeting, Eugene, Oregon, November 20-22, 1997

"Advances in the Biologic Therapy of Cancer", Central Oregon Oncology Conference, Bend, Oregon, February 5-7, 1998.

"Vaccine Therapy for Breast Cancer and Melanoma", Central Oregon Oncology Conference, Bend, Oregon, February 5-7, 1998.

"Advances in Malignant Melanoma", Second Jordanian Oncology Conference/Second Pan Arab Cancer Conference/Fourth French Arab Cancer Foundation Conference/Second Arab American Cancer Foundation Conference, Amman, Jordan, April 16, 1998.

"Overview and Recent Developments of Cytokine Cancer Therapy", Second Jordanian Oncology Conference/Second Pan Arab Cancer Conference/Fourth French Arab Cancer Foundation Conference/Second Arab American Cancer Foundation Conference, Amman, Jordan, April 17, 1998.

"Gene-Modified Whole Tumor Cell Vaccines", Southwest Oncology Group Spring Meeting, Atlanta, Georgia, April 24,1998.

Local Site Moderator for CME videoconference, "The New Standard of Surgical Care for Melanoma Staging: Minimally Invasive Selective Lymphadenectomy", Portland, OR, June 11, 1998.

"Advances in the Biologic Therapy of Cancer, presentation to graduating oncology class, School of Naturopathic Medicine, Portland, Oregon, June 23, 1998.

"Gene Modified Tumor Vaccine for Malignant Melanoma", Department of Dermatology invited speaker, OHSU, Portland, Oregon , June 30, 1998.

"Breast Cancer: Current Issues", A Day For You Conference, Portland, Oregon, October 10, 1998.

"Hodgkin's Disease", Hematology/Oncology Noon Conference, Providence Portland Medical Center, Portland, Oregon, November 3, 1998.

"Post Transplant Immunotherapy", presentation to Foundation for the Accreditation of Hematopoietic Cell Therapy, Portland, Oregon, January 18, 1999.

"Immunotherapy for Prostate Cancer", Providence Portland Medical Center, Man-to-Man Prostate Cancer Support Group, Portland, Oregon, January 21, 1999.

"Issues in Breast Cancer Management", short presentation and symposia host, Providence Portland Medical Center, Portland, Oregon, February 11, 1999.

Positive Perspectives: Creating Hope for Cancer Patients, Portland, Oregon, April 28, 1999.

"Peptide Vaccines for Intermediate Thickness Melanoma", Immunomolecular Therapeutics Committee, Southwest Oncology Group Spring Group Meeting, Phoenix, AZ, April 30, 1999.

"Peptide Vaccines for Intermediate Thickness Melanoma", Melanoma Committee, Southwest Oncology Group Spring Group Meeting, Phoenix, AZ, May 2, 1999.

"Outsmarting Cancer: Will Cancer Vaccines Reverse the Immune System's Ignorance of Tumors?", Medical Grand Rounds, Providence Portland Medical Center, Portland, Oregon, May 26, 1999.

"Prostate Cancer Research and Clinical Trials", Good Samaritan Hospital Prostate Cancer Support Group, Portland, Oregon, July 6, 1999.

Prostate Cancer, Beaverton Rotary Club, Beaverton, Oregon, May 26, 1999.

"Vaccinating Against Breast Cancer", invited lecture, Parkrose High School, Portland, Oregon, December 7, 1999.

"Renal Cell Cancer", Hematology/Oncology Noon Conference, Providence Portland Medical Center, Portland, Oregon December 7, 1999.

Gene Therapy-based Vaccine Development in Melanoma, invited discussant, 36th Annual Meeting, American Society of Clinical Oncology, New Orleans, Louisiana, May 2000.

Immunobiology and Biologic Therapy, invited discussant, American Society of Clinical Oncology Annual Meeting, San Francisco, California, May 2001.

"Vaccine Trial In High Risk Stage II-III Melanoma Patients Receiving a gp-100 Peptide Vaccination", invited lecture, Chiles Foundation Symposium, Immuntherapeutische Strategien zur Behandlung solider Tumore, Munich, Germany, June 2001. Adjuvant Immunization of HLA-A2+ Melanoma Patients with a Modified gp100 Peptide, College of Medicine and Dentistry, New Jersey, April 2002.

Adjuvant Immunization of HLA-A2+ Melanoma Patients with a Modified gp100 Peptide, Tegernsee Conference, Munich, Germany, June 2002.

Adjuvant Immunization of HLA-A2+ Melanoma Patients with a Modified gp100 Peptide, John Wayne Cancer Institute, October 2002.

High-Dose IL2 in Renal and Metastatic Cancers presentation, IL-2 Preceptorship, Providence Cancer Research Center, January 17, 2002, May 2, 2002, October 10, 2002, April 10, 2003, June 12, 2003, October 9, 2003, February 19, 2004, and May 20, 2004.

Therapeutic Promise of Melanoma Research, American Society of Clinical Oncology Annual Meeting, New Orleans, June 2004 (this was presented twice at the annual ASCO meeting).

 
Updated: June 26, 2006